Viewing Study NCT05817318



Ignite Creation Date: 2024-05-06 @ 6:51 PM
Last Modification Date: 2024-10-26 @ 2:56 PM
Study NCT ID: NCT05817318
Status: RECRUITING
Last Update Posted: 2023-10-10
First Post: 2023-03-14

Brief Title: Renal Denervation in Patients With Recurrent Atrial Fibrillation After Successful Pulmonary Vein Isolation
Sponsor: Insel Gruppe AG University Hospital Bern
Organization: Insel Gruppe AG University Hospital Bern

Study Overview

Official Title: Renal Denervation in Patients With Recurrent Atrial Fibrillation After Successful Pulmonary Vein Isolation REDE-AF a National Multi-centre Prospective Single-arm Pre-to-post Treatment Medical-device Study
Status: RECRUITING
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: REDE-AF
Brief Summary: The aim of this study is to investigate whether renal denervation can reduce arrhythmia burden in patients with recurrent paroxysmal atrial fibrillation despite durable pulmonary vein isolation
Detailed Description: Pulmonary vein isolation is the treatment of choice in symptomatic patients with paroxysmal atrial fibrillation Despite durable pulmonary vein isolation 15 of patients continue to have episodes of atrial fibrillation because of triggers of atrial fibrillation localized outside the pulmonary veins Additional ablation of these triggers is difficult because they often cannot be localized The autonomous nervous system does influence these triggers and modulation of the autonomous nervous system with the goal to reduce sympathetic activity may be an alternative approach to suppress these extra-pulmonary vein triggers Renal denervation does reduce sympathetic activity and is successfully used to treat drug-resistant arterial hypertension The combination of pulmonary vein isolation with renal denervation has already been shown to be superior to pulmonary vein isolation alone in patients with paroxysmal atrial fibrillation regarding arrhythmia-free outcome The investigators hypothesize that renal denervation can suppress atrial fibrillation in patients with recurrent episodes of paroxysmal atrial fibrillation despite durable isolation of the pulmonary veins

The best way to assess atrial fibrillation burden is with an implantable cardiac monitor ICM which the investigators will use both before and after renal denervation to gather detailed data on daily atrial fibrillation burden

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None